Company
Novo Nordisk
Novo Nordisk has 46 drugs tracked on RxWires: 7 post-market, 1 approved, 22 in Phase 3, 2 in Phase 2, 12 in Phase 1.
- Ticker
- NVO
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| metformin | Post-Market | Type 2 Diabetes |
| insulin aspart | Post-Market | Diabetes |
| Semaglutide | Post-Market | Cardiovascular Risk |
| Insulin Degludec 100 UNT/ML [Tresiba] | Post-Market | Type 2 Diabetes Mellitus |
| biphasic insulin aspart | Post-Market | Diabetes |
| liraglutide | Post-Market | Diabetes |
| biphasic insulin aspart 30 | Post-Market | Diabetes |
| NOVOLIN N | Approved | |
| NNC0487-0111 | Phase 3 | Obesity |
| turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder |
| IcoSema | Phase 3 | Diabetes Mellitus, Type 2 |
| CagriSema | Phase 3 | Hypertension |
| KBP-5074 | Phase 3 | Chronic Kidney Diseases |
| Denecimig | Phase 3 | Haemophilia A |
| Somapacitan | Phase 3 | Growth Hormone Deficiency in Children |
| NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) |
| insulin degludec | Phase 3 | Diabetes |
| somatropin | Phase 3 | Growth Disorder |
| Metformin on top of intensive insulin therapy | Phase 3 | Type 2 Diabetes Mellitus |
| Cagrilintide | Phase 3 | Obesity |
| sulfonylurea | Phase 3 | Diabetes |
| Faster-acting insulin aspart | Phase 3 | Diabetes |
| insulin degludec/insulin aspart | Phase 3 | Diabetes |
| Insulin degludec/liraglutide | Phase 3 | Diabetes |
| insulin detemir | Phase 3 | Diabetes |
| repaglinide | Phase 3 | Diabetes |
| repaglinide and metformin combination tablet | Phase 3 | Diabetes |
| inhaled human insulin | Phase 3 | Diabetes |
| Liraglutide Pen Injector [Saxenda] | Phase 3 | Pre Diabetes |
| Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 |
| activated recombinant human factor VII | Phase 2 | Acquired Bleeding Disorder |
| recombinant interleukin-21 | Phase 2 | Cancer |
| UBT251 | Phase 1 | Obesity |
| NNC0642-1895 | Phase 1 | |
| NNC4004-0002 | Phase 1 | Hyperuricemia |
| NNC9836-0001 | Phase 1 | Diabetes Mellitus, Type 2 |
| NNC0113-0987 | Phase 1 | Diabetes |
| nonacog beta pegol | Phase 1 | Congenital Bleeding Disorder |
| NNC0113-2023 | Phase 1 | Diabetes Mellitus, Type 2 |
| Advate® | Phase 1 | Congenital Bleeding Disorder |
| NNC9204-1513 | Phase 1 | Diabetes |
| NNC0194-0499 | Phase 1 | Metabolism and Nutrition Disorder |
| NNC0491-6075 | Phase 1 | Healthy Volunteers |
| pump | Phase 1 | Diabetes |
| Placebo treatment | Not Applicable | Diabetes Mellitus, Type 1 |
| dual-action insulin analog | Not Applicable | Diabetes Mellitus, Type 2 |
Latest
Follow Novo Nordisk on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.